Targeted therapies have limitations in treating ovarian cancer due to immune evasion and poor drug penetrability. Synthetic iMSCs offer a promising solution by delivering therapeutic cargo directly to the tumor microenvironment, activating immune responses and potentially improving patient outcomes. This innovative approach represents a significant advancement in ovarian cancer treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing